| Varieties: | Parasite Disease Prevention Medicine |
|---|---|
| Component: | Chemical Synthetic Drugs |
| Type: | The First Class |
| Product Information | |
| Composition | Each ml contains: Tramadol 60 mg/mL |
| DESCRIPTION | Tramadol is a synthetic codeine derivative, μ agonist, used as an analgesic for a variety of acute and chronic painful syndromes. |
| BIOACTIVITY | TRAM LD has a double mechanism of action, on the one hand it binds to the opioid receptors of the Mu type and on the other hand it inhibits the reuptake of Noradrenaline and Serotonin, in such a way that it increases the activity of these neurotransmitters. This dual mode of action gives it a powerful synergistic action, leading to analgesia comparable to meperidine or codeine. Its duration of action is 6 to 8 hours. |
| INDICATIONS OF USE | TRAM LD, is indicated for the control of somatic and / or visceral pain of moderate to severe degree and of acute or chronic origin (fractures, dislocations, contusions, osteoarthritis, neuropathies, etc.). TRAM LD can be administered during anesthetic premedication in order to improve intraoperative analgesia and provide the patient with a comfortable awakening. TRAM LD in combination with major tranquilizers increases the sedative action and justifies the dose reduction. TRAM LD is used in the treatment of postoperative pain of outpatients and hospitalized patients, presenting itself as an effective alternative in the majority of abdomen, mastectomy, traumatology and spine surgeries. The combination of TRAM LD with non-steroidal anti-inflammatory drugs increases its effectiveness, producing a multimodal pain relief action. |
| DOSAGE | Canines and Felines 1-2mg / Kg .; SC, IM, Slow EV, Epidural Sports horses 1 mg / kg; Slow, Epidural EV Infusion Interval between doses: administer every 6 to 8 hours. |
| INTERACTIONS | MAO inhibitors (selegiline) and cytochrome P 450 inhibitors (cimetidine, ketoconazole, erythromycin) can enhance the toxicity of Tramadol by increasing its plasma concentration. Its administration together with agonists / antagonists (for example buprenorphine, nalbuphine) may reduce the analgesic effect. When combined with agonists? 2, such as xylazine or medetomidine, respiratory depression can be observed. In these cases, it is recommended to use the IM route, reduce the final dose of the agonists? 2 and contemplate the need to atropinize the patient. |
